Related articles

Daraxonrasib

KRAS-targeting drug that doubled survival in metastatic pancreatic cancer and prompted a standing ovation at ASCO.

• Oncologists in Chicago and Madrid Erupt in Standing Ovations for Breakthroughs Against Pancreatic and Lung Cancer